What is the 13F Pro Quality Score for GKOS?

13F Pro ranks GLAUKOS Corp (GKOS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GKOS's current score at https://13fpro.ai/research/GKOS (free sign-up required for the full ranking).

Which hedge funds own the most GKOS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GKOS include BlackRock,, JANUS HENDERSON GROUP PLC, PRIMECAP MANAGEMENT CO/CA/. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/GKOS as soon as new 13F filings post.

Where does 13F Pro source GKOS data?

All GLAUKOS Corp fundamentals and ownership data come directly from SEC EDGAR. GLAUKOS Corp files with the SEC under CIK 1192448. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GKOS in?

GLAUKOS Corp (GKOS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GKOS research updated on 13F Pro?

GKOS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GLAUKOS Corp(GKOS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1192448 GKOS stock profile & AI dashboard →

13F Pro Quality Score

39.2/100

Rank #1,982 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

86.0/100

Profitability

23.1/100

Balance Sheet

19.4/100

Earnings Quality

30.0/100

Free Cash Flow

20.4/100

Institutional Flow

72.1/100

Revenue Scale

37.3/100

Dilution Risk

14.5/100

GKOS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GLAUKOS Corp (GKOS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GKOS at 39.2/100 on a 32-signal composite quality model, placing it at rank #1,982 of 2,879 stocks — the bottom half of the AI-ranked universe. GKOS scores in the top quartile across revenue growth (86.0). Areas of concern include balance sheet strength (19.4) and free cash flow (20.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), GLAUKOS Corp reports quarterly revenue of $150.6M, net income of $-19.8M, free cash flow of $-16.5M. Top institutional holders of GKOS by reported 13-F value include BlackRock,, JANUS HENDERSON GROUP PLC, PRIMECAP MANAGEMENT CO/CA/, based on the most recent SEC filings. GKOS trades on the NYSE exchange and files with the SEC under CIK 1192448. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GKOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GLAUKOS Corp directly from SEC EDGAR. GLAUKOS Corp's 13F Pro composite quality score has ranged between 8 and 68 since 2021, currently 39.2 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about GLAUKOS Corp

Quirks, history, and lore behind GKOS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on NYSE · headquartered in Southern California.
2
The Numbers
Annual revenue in the range of $300–400 million — modest in size but growing fast, with a focus on a market that affects tens of millions of Americans quietly going blind.
3
The History
Founded in the early 2000s, it spent years developing a minimally invasive surgical device that could treat a leading cause of irreversible blindness without the drama of traditional surgery.
4
The Secret
Its flagship innovation is a tiny implantable stent — smaller than an eyelash — designed to drain fluid and lower pressure inside the human eye.
5
The Lore
The company's name is literally derived from the word glaucoma, the progressive eye disease it was built from day one to defeat.
6
The Giveaway
It makes the iStent — the smallest FDA-approved implant ever placed in the human body — and it's betting everything on conquering glaucoma, one microscopic device at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$150.6M

Net Income

Q1 2026

$-19.8M

Free Cash Flow

Q1 2026

$-16.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+32.3% YoY

$507.4MFY 2025

FY22 $282.9MFY23 $314.7MFY24 $383.5MFY25 $507.4M

Net Income

-28.2% YoY

$-187.7MFY 2025

FY22 $-99.2MFY23 $-134.7MFY24 $-146.4MFY25 $-187.7M

Operating Income

-63.1% YoY

$-199.6MFY 2025

FY22 $-82.3MFY23 $-128.7MFY24 $-122.4MFY25 $-199.6M

EPS (Diluted)

-18.4% YoY

$-3.28FY 2025

FY22 $-2.09FY23 $-2.78FY24 $-2.77FY25 $-3.28

Total Assets

-8.3% YoY

$893.5MFY 2025

FY22 $1.00BFY23 $940.4MFY24 $974.8MFY25 $893.5M

Op. Cash Flow

+75.9% YoY

$-14.8MFY 2025

FY22 $-33.1MFY23 $-57.8MFY24 $-61.3MFY25 $-14.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$507.4M +32.3%	$383.5M +21.9%	$314.7M +11.3%	$282.9M +25.7%	$225.0M -5.1%	$237.0M
Net Income	$-187.7M -28.2%	$-146.4M -8.7%	$-134.7M -35.8%	$-99.2M +17.6%	$-120.3M -880.3%	$15.4M
Operating Income	$-199.6M -63.1%	$-122.4M +4.9%	$-128.7M -56.4%	$-82.3M +33.4%	$-123.6M -145.7%	$-50.3M
EPS (Diluted)	$-3.28 -18.4%	$-2.77 +0.4%	$-2.78 -33.0%	$-2.09 +22.6%	$-2.70 -829.7%	$0.37
Total Assets	$893.5M -8.3%	$974.8M +3.7%	$940.4M -6.2%	$1.00B -0.3%	$1.01B +22.9%	$818.4M
Operating Cash Flow	$-14.8M +75.9%	$-61.3M -6.2%	$-57.8M -74.6%	$-33.1M -43.9%	$-23.0M -6129.8%	$-369.0K

AI Insight: GKOS Ratio Trends

GLAUKOS swung from near-breakeven in Q3 2025 to a massive Q4 2025 loss, but Q1 2026 shows sharp recovery with all profitability metrics improving.

• Operating margin rebounded from -97.7% in Q4 2025 to -13.2% in Q1 2026, reversing a severe one-quarter deterioration.

• Net profit margin improved from -93.4% in Q4 2025 to -13.1% in Q1 2026, suggesting one-off charges or restructuring in Q4.

• ROA trending from -6.5% in Q3 2025 to -59.8% in Q4 2025, then to -8.9% in Q1 2026, indicating volatility masking underlying asset efficiency.

⚠ Q4 2025 saw a dramatic collapse across all metrics (OpMargin -97.7%, ROE -81.5%, ROIC -85.3%); root cause and recurrence risk unclear.

⚠ TTM profitability remains severely negative (OpMargin -36.0%, ROIC -29.6%), indicating ongoing losses despite Q1 2026 bounce.

Get alerted when GKOS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GLAUKOS Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GKOS

BlackRock, Inc.
$978.6M9,090,029 sh
JANUS HENDERSON GROUP PLC
$575.8M5,348,395 sh
PRIMECAP MANAGEMENT CO/CA/
$362.9M3,370,628 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$345.4M3,208,363 sh
VANGUARD CAPITAL MANAGEMENT LLC
$270.1M2,508,771 sh
STATE STREET CORP
$235.0M2,182,617 sh
AMERIPRISE FINANCIAL INC
$173.4M1,610,774 sh
ALLIANCEBERNSTEIN L.P.
$157.8M1,397,556 sh
CITADEL ADVISORS LLC
$155.8M1,446,926 sh
Holocene Advisors, LP
$149.0M1,383,715 sh

Fund	Value	Shares
BlackRock, Inc.	$978.6M	9,090,029
JANUS HENDERSON GROUP PLC	$575.8M	5,348,395
PRIMECAP MANAGEMENT CO/CA/	$362.9M	3,370,628
VANGUARD PORTFOLIO MANAGEMENT LLC	$345.4M	3,208,363
VANGUARD CAPITAL MANAGEMENT LLC	$270.1M	2,508,771
STATE STREET CORP	$235.0M	2,182,617
AMERIPRISE FINANCIAL INC	$173.4M	1,610,774
ALLIANCEBERNSTEIN L.P.	$157.8M	1,397,556
CITADEL ADVISORS LLC	$155.8M	1,446,926
Holocene Advisors, LP	$149.0M	1,383,715

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GKOS on your watchlist

Track score changes the day GLAUKOS Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GKOS a good stock to buy?

13F Pro's AI-powered analysis of GLAUKOS Corp (GKOS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GKOS are available on the GKOS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GKOS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GKOS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GLAUKOS Corp's investment landscape.